Home › Myasthenia Gravis › Nevada › Las Vegas
Myasthenia Gravis clinical trials in Las Vegas, NV
3 studies for Myasthenia Gravis are looking for participants at sites in and around Las Vegas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RecruitingObservational study
- Profound Research LLC at Las Vegas Neurology Center, Las Vegas
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RecruitingPhase 2
- Profound Research LLC at Las Vegas Neurology Center, Las Vegas
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
RecruitingPhase 2
- Las Vegas Neurology Center, Las Vegas
About Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease that weakens the muscles under your control. Find out about MG causes, symptoms, and treatment.
More about Myasthenia Gravis on MedlinePlus
Myasthenia Gravis trials in other cities
- Tampa, FL12 studies
- Houston, TX11 studies
- Durham, NC10 studies
- Boca Raton, FL10 studies
- Columbus, OH8 studies
- Miami, FL7 studies
- New York City, NY7 studies
- Milwaukee, WI7 studies
- St. Louis, MO7 studies
- Boston, MA6 studies
- Washington, DC6 studies
- San Francisco, CA6 studies
Other studies in Las Vegas
- Obesity27 studies
- Overweight23 studies
- Type 2 Diabetes18 studies
- Non-Small Cell Lung Cancer13 studies
- Major Depressive Disorder13 studies
- Breast Cancer10 studies
- Alzheimer's Disease8 studies
- Acute Myeloid Leukemia8 studies
- Prostate Cancer8 studies
- Cancer (all types)8 studies
- Schizophrenia7 studies
- Atherosclerosis7 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.